-
1
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
DOI 10.1038/nature00766
-
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954. (Pubitemid 34716871)
-
(2002)
Nature
, vol.417
, Issue.6892
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
Teague, J.7
Woffendin, H.8
Garnett, M.J.9
Bottomley, W.10
Davis, N.11
Dicks, E.12
Ewing, R.13
Floyd, Y.14
Gray, K.15
Hall, S.16
Hawes, R.17
Hughes, J.18
Kosmidou, V.19
Menzies, A.20
Mould, C.21
Parker, A.22
Stevens, C.23
Watt, S.24
Hooper, S.25
Wilson, R.26
Jayatilake, H.27
Gusterson, B.A.28
Cooper, C.29
Shipley, J.30
Hargrave, D.31
Pritchard-Jones, K.32
Maitland, N.33
Chenevix-Trench, G.34
Riggins, G.J.35
Bigner, D.D.36
Palmleri, G.37
Cossu, A.38
Flanagan, A.39
Nicholson, A.40
Ho, J.W.C.41
Leung, S.Y.42
Yuen, S.T.43
Weber, B.L.44
Seigler, H.F.45
Darrow, T.L.46
Paterson, H.47
Marais, R.48
Marshall, C.J.49
Wooster, R.50
Stratton, M.R.51
Futreal, P.A.52
more..
-
2
-
-
0037442752
-
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation
-
Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, et al. (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759. (Pubitemid 36231971)
-
(2003)
Cancer Research
, vol.63
, Issue.4
, pp. 756-759
-
-
Satyamoorthy, K.1
Li, G.2
Gerrero, M.R.3
Brose, M.S.4
Volpe, P.5
Weber, B.L.6
Van Belle, P.7
Elder, D.E.8
Herlyn, M.9
-
3
-
-
84863673204
-
Improved survival with MEK inhibition in BRAF-mutated melanoma
-
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, et al. (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107-114.
-
(2012)
N Engl J Med
, vol.367
, pp. 107-114
-
-
Flaherty, K.T.1
Robert, C.2
Hersey, P.3
Nathan, P.4
Garbe, C.5
-
4
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
-
5
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
-
(2010)
N Engl J Med
, vol.363
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
Ribas, A.4
McArthur, G.A.5
-
6
-
-
83255191650
-
Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort
-
Si L, Kong Y, Xu X, Flaherty KT, Sheng X, et al. (2012) Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 48: 94-100.
-
(2012)
Eur J Cancer
, vol.48
, pp. 94-100
-
-
Si, L.1
Kong, Y.2
Xu, X.3
Flaherty, K.T.4
Sheng, X.5
-
7
-
-
84978034236
-
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
-
Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, et al. (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29: 1239-1246.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1239-1246
-
-
Long, G.V.1
Menzies, A.M.2
Nagrial, A.M.3
Haydu, L.E.4
Hamilton, A.L.5
-
8
-
-
84862584008
-
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma
-
Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, et al. (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18: 3242-3249.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 3242-3249
-
-
Menzies, A.M.1
Haydu, L.E.2
Visintin, L.3
Carlino, M.S.4
Howle, J.R.5
-
9
-
-
84864722943
-
NRAS mutation status is an independent prognostic factor in metastatic melanoma
-
Jakob JA, Bassett RL, Jr., Ng CS, Curry JL, Joseph RW, et al. (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118: 4014-4023.
-
(2012)
Cancer
, vol.118
, pp. 4014-4023
-
-
Jakob, J.A.1
Bassett Jr., R.L.2
Ng, C.S.3
Curry, J.L.4
Joseph, R.W.5
-
10
-
-
2942607408
-
Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis
-
Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, et al. (2004) Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3: 6.
-
(2004)
J Carcinog
, vol.3
, pp. 6
-
-
Houben, R.1
Becker, J.C.2
Kappel, A.3
Terheyden, P.4
Brocker, E.B.5
-
11
-
-
84856363696
-
First-line temozolomide combined with bevacizumab in metastatic melanoma: A multicentre phase II trial (SAKK 50/07)
-
von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, et al. (2012) First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol 23: 531-536.
-
(2012)
Ann Oncol
, vol.23
, pp. 531-536
-
-
Von Moos, R.1
Seifert, B.2
Simcock, M.3
Goldinger, S.M.4
Gillessen, S.5
-
12
-
-
33845592531
-
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: A study based on mutation screening by pyrosequencing
-
DOI 10.1097/01.cmr.0000232300.22032.86, PII 0000839020061200000001
-
Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, et al. (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16: 471-478. (Pubitemid 44934704)
-
(2006)
Melanoma Research
, vol.16
, Issue.6
, pp. 471-478
-
-
Edlundh-Rose, E.1
Egyhazi, S.2
Omholt, K.3
Mansson-Brahme, E.4
Platz, A.5
Hansson, J.6
Lundeberg, J.7
-
13
-
-
84872595484
-
BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma
-
Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, et al. (2013) BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. J Invest Dermatol 133: 509-517.
-
(2013)
J Invest Dermatol
, vol.133
, pp. 509-517
-
-
Mann, G.J.1
Pupo, G.M.2
Campain, A.E.3
Carter, C.D.4
Schramm, S.J.5
-
14
-
-
84873809917
-
Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes
-
Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, et al. (2012) Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol 19: 4314-4321.
-
(2012)
Ann Surg Oncol
, vol.19
, pp. 4314-4321
-
-
Moreau, S.1
Saiag, P.2
Aegerter, P.3
Bosset, D.4
Longvert, C.5
-
15
-
-
79251474400
-
Clinical correlates of NRAS and BRAF mutations in primary human melanoma
-
Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, et al. (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17: 229-235.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 229-235
-
-
Ellerhorst, J.A.1
Greene, V.R.2
Ekmekcioglu, S.3
Warneke, C.L.4
Johnson, M.M.5
-
16
-
-
0346728596
-
Determinants of BRAF mutations in primary melanomas
-
Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, et al. (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95: 1878-1890.
-
(2003)
J Natl Cancer Inst
, vol.95
, pp. 1878-1890
-
-
Maldonado, J.L.1
Fridlyand, J.2
Patel, H.3
Jain, A.N.4
Busam, K.5
-
17
-
-
1842428668
-
Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas
-
DOI 10.1158/1078-0432.CCR-1169-3
-
Shinozaki M, Fujimoto A, Morton DL, Hoon DS (2004) Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10: 1753-1757. (Pubitemid 38435567)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.5
, pp. 1753-1757
-
-
Shinozaki, M.1
Fujimoto, A.2
Morton, D.L.3
Hoon, D.S.B.4
-
18
-
-
24344490303
-
BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival
-
DOI 10.1111/j.0022-202X.2005.23788.x
-
Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, et al. (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125: 312-317. (Pubitemid 41648165)
-
(2005)
Journal of Investigative Dermatology
, vol.125
, Issue.2
, pp. 312-317
-
-
Akslen, L.A.1
Angelini, S.2
Straume, O.3
Bachmann, I.M.4
Molven, A.5
Hemminki, K.6
Kumar, R.7
-
19
-
-
18144409161
-
Clinical significance of BRAF mutations in metastatic melanoma
-
Chang DZ, Panageas KS, Osman I, Polsky D, Busam K, et al. (2004) Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med 2: 46.
-
(2004)
J Transl Med
, vol.2
, pp. 46
-
-
Chang, D.Z.1
Panageas, K.S.2
Osman, I.3
Polsky, D.4
Busam, K.5
-
20
-
-
0041333110
-
BRAF mutations in metastatic melanoma: A possible association with clinical outcome
-
Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, et al. (2003) BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9: 3362-3368. (Pubitemid 37082731)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.9
, pp. 3362-3368
-
-
Kumar, R.1
Angelini, S.2
Czene, K.3
Sauroja, I.4
Hahka-Kemppinen, M.5
Pyrhonen, S.6
Hemminki, K.7
-
21
-
-
84867298938
-
The prognostic value of BRAF mutation in colorectal cancer and melanoma: A systematic review and meta-analysis
-
Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 7: e47054.
-
(2012)
PLoS One
, vol.7
-
-
Safaee Ardekani, G.1
Jafarnejad, S.M.2
Tan, L.3
Saeedi, A.4
Li, G.5
-
22
-
-
77952239974
-
Cutaneous melanoma in the elderly: Epidemiology, prognosis and treatment
-
Lasithiotakis KG, Petrakis IE, Garbe C (2010) Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Res 20: 163-170.
-
(2010)
Melanoma Res
, vol.20
, pp. 163-170
-
-
Lasithiotakis, K.G.1
Petrakis, I.E.2
Garbe, C.3
-
23
-
-
79957929511
-
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: An analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database
-
Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, et al. (2011) Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 29: 2199-2205.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2199-2205
-
-
Thompson, J.F.1
Soong, S.J.2
Balch, C.M.3
Gershenwald, J.E.4
Ding, S.5
-
24
-
-
0035880957
-
Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
-
Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634. (Pubitemid 32786275)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.16
, pp. 3622-3634
-
-
Balch, C.M.1
Soong, S.-J.2
Gershenwald, J.E.3
Thompson, J.F.4
Reintgen, D.S.5
Cascinelli, N.6
Urist, M.7
McMasters, K.M.8
Ross, M.I.9
Kirkwood, J.M.10
Atkins, M.B.11
Thompson, J.A.12
Coit, D.G.13
Byrd, D.14
Desmond, R.15
Zhang, Y.16
Liu, P.-Y.17
Lyman, G.H.18
Morabito, A.19
-
25
-
-
0035881074
-
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
-
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648. (Pubitemid 32786276)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.16
, pp. 3635-3648
-
-
Balch, C.M.1
Buzaid, A.C.2
Soong, S.-J.3
Atkins, M.B.4
Cascinelli, N.5
Coit, D.G.6
Fleming, I.D.7
Gershenwald, J.E.8
Houghton Jr., A.9
Kirkwood, J.M.10
McMasters, K.M.11
Mihm, M.F.12
Morton, D.L.13
Reintgen, D.S.14
Ross, M.I.15
Sober, A.16
Thompson, J.A.17
Thompson, J.F.18
-
26
-
-
79953723136
-
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: A meta-analysis
-
Lee JH, Choi JW, Kim YS (2011) Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164: 776-784.
-
(2011)
Br J Dermatol
, vol.164
, pp. 776-784
-
-
Lee, J.H.1
Choi, J.W.2
Kim, Y.S.3
-
27
-
-
34250307902
-
Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma
-
DOI 10.1158/1055-9965.EPI-06-1038
-
Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, et al. (2007) Number of nevi and early-life ambient UV exposure are associated with BRAFmutant melanoma. Cancer Epidemiol Biomarkers Prev 16: 991-997. (Pubitemid 46910102)
-
(2007)
Cancer Epidemiology Biomarkers and Prevention
, vol.16
, Issue.5
, pp. 991-997
-
-
Thomas, N.E.1
Edmiston, S.N.2
Alexander, A.3
Millikan, R.C.4
Groben, P.A.5
Hao, H.6
Tolbert, D.7
Berwick, M.8
Busam, K.9
Begg, C.B.10
Mattingly, D.11
Ollila, D.W.12
Chiu, K.T.13
Hummer, A.14
Lee-Taylor, J.15
Conway, K.16
-
28
-
-
84874518093
-
Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma
-
Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, et al. (2013) Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 15: 220-226.
-
(2013)
J Mol Diagn
, vol.15
, pp. 220-226
-
-
Greaves, W.O.1
Verma, S.2
Patel, K.P.3
Davies, M.A.4
Barkoh, B.A.5
-
29
-
-
84864042630
-
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma
-
Colombino M, Capone M, Lissia A, Cossu A, Rubino C, et al. (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30: 2522-2529.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2522-2529
-
-
Colombino, M.1
Capone, M.2
Lissia, A.3
Cossu, A.4
Rubino, C.5
-
30
-
-
84857030136
-
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
-
Capper D, Berghoff AS, Magerle M, Ilhan A, Wohrer A, et al. (2012) Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 123: 223-233.
-
(2012)
Acta Neuropathol
, vol.123
, pp. 223-233
-
-
Capper, D.1
Berghoff, A.S.2
Magerle, M.3
Ilhan, A.4
Wohrer, A.5
-
31
-
-
74949143594
-
Final version of 2009 AJCC melanoma staging and classification
-
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
-
(2009)
J Clin Oncol
, vol.27
, pp. 6199-6206
-
-
Balch, C.M.1
Gershenwald, J.E.2
Soong, S.J.3
Thompson, J.F.4
Atkins, M.B.5
|